BioStock Studio: Scandion Oncology’s CEO comments on ongoing rights issue
Scandion Oncology recently announced that the company is raising 236 MSEK through a fully guaranteed rights issue. The subscription period runs from November 26 through December 10. BioStock caught up with Scandion Oncology’s CEO Bo Rode Hansen via video link to learn more about how the company plans to make the best of the raised capital.
Watch the full interview with Scandion Oncology's CEO Bo Rode Hansen at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se